Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?
Since the presence of an M-component is an essential disease feature in both multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM), the decrease in the M-protein size applied for response in MM is also a crucial criteria for assessing response in WM. However, WM frequently displays lymphoma-like features that should be included in the response criteria.
Department of Hematology, Institute of Hematology and Oncology, Postgraduate School of Hematology Farreras Valentí, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Joan
J
Bladé
Silvia
S
Montoto
Laura
L
Rosiñol
Emili
E
Montserrat
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy*; D011379:Prognosis; D012074:Remission Induction; D017211:Treatment Failure; D016896:Treatment Outcome; D008258:Waldenstrom Macroglobulinemia / Q000097:blood* / Q000188:drug therapy*
D000970:Antineoplastic Agents; D007075:Immunoglobulin M